Rite Aid, Patient Portal offer new delivery service to discharged patients
BALDWINSVILLE, N.Y. Patient Portal Technologies on Wednesday announced today that the company is partnering with Rite Aid to pilot a unique prescription delivery service to hospital patients.
The pilot program will be conducted with a Philadelphia healthcare system and supported by select Philadelphia Rite Aid locations.
Patient Portal’s MedEx Home Delivery will offer free home delivery of prescriptions for hospital patients who are being discharged, eliminating their need to stop for the medication on their way home.
“In today’s competitive healthcare landscape, hospitals are looking for trusted partners to deliver simple solutions that enhance long-term, customized care for patients,” stated Kevin Kelly, chief executive officer of Patient Portal. “Our objective is to continue to manage the patient experience beyond the traditional four walls of the hospital. Managing the patient relationship and providing services that enhance wellness is essential.”
Amgen, Wyeth revise labeling for Enbrel
PHILADELPHIA and THOUSAND OAKS, Calif. Amgen and Wyeth Pharmaceuticals have informed health care professionals of revisions to prescribing information for their rheumatoid arthritis and psoriasis medication Enbrel.
The revisions include a boxed warning about infections, including serious infections leading to hospitalization or death that have been observed in patients treated with Enbrel.
Infections have included bacterial sepsis and tuberculosis. The adverse reactions section of the label was updated to include information regarding global clinical studies and the rate of occurrence of tuberculosis in patients treated with Enbrel.
FDA approves Advair for wider use with COPD patients
WASHINGTON The Food and Drug Administration has approved GlaxoSmithKline’s asthma drug Advair to be used more widely to treat patients with chronic obstructive pulmonary disease, according to published reports. The drug had been approved to prevent wheezing and control other symptoms in COPD patients.
GSK’s approval comes the same day as rival AstraZeneca said it also was seeking FDA approval to sell its drug Symbicort for COPD.
COPD, an often-fatal lung condition with no cure, is a major market with more than 12 million Americans suffering from the disease, and another 12 million who are likely not diagnosed, according to the National Institutes of Health.
The FDA’s approval allows GSK to promote its product to COPD patients who experience flare-ups of the disease, which includes emphysema and chronic bronchitis.